Zoetis Inc.

Company facts

Industry

Pharmaceutical Preparations

Headquarters

Parsippany, New Jersey

Most recent report

10-Q, filed Nov 5, 2026

Incorporated

N/A

Filings on record

1,004+ filings

On EDGAR

CIK 1555280

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 0 positive, 10 notable, and 4 negative flags.

• Financial Statements (Item 1)

  Securities class action filed May 2026; IRS dispute ~$450M; convertible notes; buyback pace; segment results.
  Notable

  • Fiscal year alignment eliminated one-month reporting lag for non-U.S. subsidiaries, recasting prior periods.
  • $78M impairment on PetMedix in-process R&D assets in Q3 2026 due to updated development and commercial assumptions.
  • Uncertain tax positions of $228M plus $65M interest/penalties at Sep 30, 2026, up from $222M plus $52M at Dec 31, 2025.
  • Convertible senior notes of $2B issued Dec 2025; $1.97B net proceeds used for buybacks and capped calls.
  Negative

  • IRS seeks ~$450M additional tax for 2017-2018 on deemed repatriation; company disputes and is appealing.
  • Securities class action filed May 2026, amended Oct 2026, alleging false statements on companion animal demand. Early stage.

• Management's Discussion (Item 2)

  Revenue down 1% Q3, net income down 18%; U.S. companion animal sales fell 8% Q3, 10% YTD.
  Notable

  • Fiscal year alignment shifted Dec 2025 international sales into Q1 2026, boosting YTD comps.
  • International segment revenue grew 4% in Q3 2026 and 9% YTD, helped by FX and livestock growth.
  • Issued $2.0B convertible notes at 0.250% due 2029; used $1,783M for share repurchases.
  • Share repurchases totaled $1,659M in first nine months of 2026; $770M remaining under $6B authorization.
  Negative

  • $89M impairment on PetMedix in-process R&D assets in Q3 2026, reflecting lower development expectations.
  • U.S. companion animal revenue fell 8% in Q3 2026 and 10% YTD, driven by competition and price sensitivity.

• Unregistered Sales and Repurchases (Item 2)

  Large buyback program with $770M remaining; $1.8B spent in 9 months, key for capital allocation.
  Notable

  • $6B buyback program authorized Aug 2024; $770M remaining as of Sep 30, 2026, no expiration date.
  • Convertible note proceeds: $248M used for 2.1M shares at offering, then $1.5B for 12.3M shares by Mar 2026.

What changed: Sep 2026 vs. Jun 2026

About 5% of ZTS's Sep 2026 10-Q is new information. 26 paragraphs were added, 184 changed, and 30 removed. Below are the most important lines SECSift identified.

• Item 2 100
• Item 1 55
• Item 6 3
• Item 4 2
• Item 5 1